Skip to Content

ARK Genomic Revolution ETF ARKG

Medalist Rating as of | See ARK Investment Hub

Morningstar’s Analysis ARKG

Will ARKG outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

A lowering of its Process Pillar rating is the primary driver of ARK Genomic Revolution ETF's downgrade to a Morningstar Medalist Rating of Negative from Neutral.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a sizable cost advantage over competitors, priced within the second-cheapest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings ARKG

  • Current Portfolio Date
  • Equity Holdings 39
  • Bond Holdings 1
  • Other Holdings 2
  • % Assets in Top 10 Holdings 51.4
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector
9.18
168,717,593
Healthcare
6.24
114,800,786
Healthcare
5.88
108,105,537
Healthcare
5.00
91,856,930
Healthcare
4.95
91,038,301
Healthcare
4.23
77,701,329
Healthcare
4.21
77,307,692
Healthcare
3.96
72,861,041
Technology
3.92
71,993,037
Healthcare
3.87
71,142,286
Healthcare